Leerink Partners analyst Danielle Antalffy maintained a Buy rating on Edwards Lifesciences on Monday, setting a price target of $100, which is approximately 19.19% above the present share price of $83.9.
Antalffy expects Edwards Lifesciences to post earnings per share (EPS) of -$0.20 for the fourth quarter of 2020.
The current consensus among 14 TipRanks analysts is for a Moderate Buy rating of shares in Edwards Lifesciences, with an average price target of $88.08.
The analysts price targets range from a high of $100 to a low of $68.
In its latest earnings report, released on 06/30/2020, the company reported a quarterly revenue of $925 million and a net profit of $229.8 million. The company's market cap is $52.16 billion.
According to TipRanks.com, Leerink Partners analyst Danielle Antalffy is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 20.6% and a 65.90% success rate.
Edwards Lifesciences Corp (NYSE:EW). engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart and Critical Care. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. Its portfolio includes technologies designed for nonsurgical replacement of heart valves. The Surgical Structural Heart portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient's heart valve. The Critical Care portfolio products through hemodynamic monitoring system measures a patient's heart function and fluid status in surgical and intensive care settings. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.